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Introduction
Resolution of inflammation is essential for the return to tissue homeostasis after an inflammatory insult, both to limit excessive organ damage, but also to initiate the repair process (Watanabe et al., 2019) . Resolution involves the suppression of pro-inflammatory active cells and the acquisition of an anti-inflammatory/recovery phenotype by immune cells.
These together drive the switch from bactericidal activity and cytokine release to tissue repair.
Macrophages are central to this process, being involved in both the acute inflammatory phase and the repair phase (Watanabe et al., 2019; Wynn and Vannella, 2016) . Inflammatory macrophages rapidly infiltrate into the target tissue, drawn by chemokines such as CCL2 or CX3CL1, and release pro-inflammatory cytokines such as TNF-a and CCL3 (Mantovani et al., 2004; Turner et al., 2014) . During the inflammatory phase, macrophages then phagocytose apoptotic cells in a process called efferocytosis. Engulfment of apoptotic cells provokes a macrophage phenotypic switch to an alternative, anti-inflammatory, pro-repair state, which promotes tissue homeostasis (Ortega-Gómez et al., 2013) . Similarly, anti-inflammatory signals can push macrophages towards a pro-efferocytosis phenotype (Fadok et al., 1998; Nepal et al., 2019; Weigert et al., 2006) assisting in the regenerative function of macrophages.
Glucocorticoids (GCs) are one of the most potent immuno-suppressive agents, which promote efferocytosis in macrophages (Desgeorges et al., 2019a; McColl et al., 2009) . GCs are also the most frequently prescribed anti-inflammatory agents, with over 1% of the UK, Danish and American populations, at one point, having received a prescription for GCs (Fardet et al., 2011; Laugesen et al., 2017; Overman et al., 2013) . GCs signal through the glucocorticoid receptor (GR), a member of the nuclear receptor superfamily, which acts as a transcription factor to regulate gene expression upon exposure to ligand (Weikum et al., 2017a) . Unlike many other nuclear receptors, GR resides in the cytoplasm, where it can interact with various signaling enzymes (Petta et al., 2016) . Upon ligand exposure, GR translocates to the nucleus to mediate its effects (Vandevyver et al., 2012a) . GR regulates transcription by transactivation and transrepression (Weikum et al., 2017a) . Suppression of pro-inflammatory cytokines occurs at the transcriptional level through GR tethering to pro-inflammatory transcription factors such as NFkB and AP-1, or by direct binding to DNA at, or nearby NFkB and AP-1 response elements and repress transcription through a tethering independent mechanism (Hudson et al., 2018; Uhlenhaut et al., 2013; Weikum et al., 2017b) . Suppression of cytokines was considered as the canonical mechanism of immunosuppression by GCs for decades (Barnes, 2011) .
However, recent studies implicated that GR dependent upregulation of anti-inflammatory genes plays an essential role in the resolution of inflammation. In particular the expression of Tsc22d3 (Gilz), Dusp1, Sphk1, Ikkb and A20 (Eddleston et al., 2007; Oh et al., 2017; Vandevyver et al., 2012b; Vettorazzi et al., 2015) are important for the anti-inflammatory properties of GCs. Little is known however, how GR cross-talks with other key regulators of the anti-inflammatory status of macrophages. One such regulator is AMP-activated protein kinase (AMPK), which controls a wide variety of metabolic functions in all cell types (Hardie et al., 2012; Herzig and Shaw, 2018) . AMPK is activated by a high AMP:ATP ratio (Hardie et al., 2012) or through diminished cellular glucose concentration (Zhang et al., 2017a) , making AMPK a sensor of cellular energy deprivation. Upon activation, AMPK phosphorylates various proteins to inhibit cellular anabolism and activate catabolism (Hardie et al., 2012; Herzig and Shaw, 2018) . For example, the fatty acid elongation enzyme, acetyl-CoA carboxylase, is phosphorylated and inhibited in response to AMPK activation, preventing the anabolic process of fatty acid elongation (Grahame Hardie, 1989) . AMPK plays a decisive role in the promotion of anti-inflammatory macrophages, initiating the repair phenotype Sag et al., 2008) . However, the mechanisms by which AMPK signaling contributes to other antiinflammatory signals is not understood. GR and AMPK were previously shown to communicate in their role as regulators of metabolism in non-immune cells (Christ-Crain et al., 2008; Nader et al., 2010; Ratman et al., 2016; Seelig et al., 2017) . We therefore sought to determine whether AMPK regulates GR anti-inflammatory actions and controls the tissue regenerative actions of macrophages.
We describe a functional interaction between GR and AMPK signaling, whereby deletion of AMPKa1 in macrophages alters GR mediated gene regulation resulting in loss of regulation of a subset of GR target genes, dubbed non-canonical, but maintenance of the regulation of traditional GR target genes. We demonstrate that GR requires AMPK activity for the development of anti-inflammatory macrophages while leaving canonical suppression of cytokine signaling intact. Loss of AMPK abrogates GC induced efferocytosis in vitro, limiting the potential anti-inflammatory actions of GCs. Furthermore, we demonstrate that detachment of the signaling between GR and AMPK in vivo, using a myeloid specific deletion of AMPKa1, impairs GC-driven resolution of tissue repair (skeletal muscle injury) and acute lung inflammation induced by endotoxin shock.
Results

The glucocorticoid receptor signals through AMPKa1 in macrophages
GCs and AMPK activators both exert anti-inflammatory actions on macrophages (Arnold et al., 2007; Ehrchen et al., 2007; Mounier et al., 2013; Xue et al., 2014) . Therefore, we sought to determine whether AMPK and GR signaling converge in macrophages. We first investigated whether the GR agonist dexamethasone (Dex) activates AMPK in bone marrow derived macrophages (BMDMs). BMDMs were treated with the AMPK activating compound 991 (Xiao et al., 2013) , Dex or a combination of both and AMPK signaling was assessed. After one hour of treatment, Dex increased the phosphorylation of AMPK at T172 as did 991, but with no additive effect of co-treatment of Dex and 991 (Fig.1A,B) . No effect was observed at 30 min of treatment by any compound (Fig.S1A) . The induced phosphorylation also resulted in increased activity of AMPK, as the downstream target ACC was also phosphorylated in response to 1 hour Dex treatment (+32%) (Fig.1A,C) . Thus, Dex activates AMPK in macrophages in a similar extent than pharmacological activators after 1 hour.
Previous reports indicate that AMPK activation may induce GR phosphorylation and activation through p38, at least in the liver (Nader et al., 2010) . Therefore, we determined how genetic loss of AMPKa1, the only AMPK catalytic subunit expressed in macrophages (Sag et al., 2008) , affects GR phosphorylation. Both wildtype (WT) and AMPKa1 knockout (AMPKa1 -/-)
BMDMs were treated with Dex for 1 hour, and phosphorylation of GR at S211 was assessed by immunoblot. Upon Dex treatment, GR phosphorylation was increased (+511%), however in macrophages lacking AMPK this increase was strongly diminished (-49%) (Fig.1D,E) . In these conditions, we did not observe any effect on p38 activation (determined through p38 phosphorylation at T180/Y182) (Fig.1D,F ). This suggests that p38 activity is independent of AMPK status and does not correlate with GR S211 phosphorylation in macrophages. Since GR S211 phosphorylation is associated with activity of GR in the nucleus (Chen et al., 2008; Treviño and Weigel, 2013) , we tested whether AMPK loss affected GR translocation to the nucleus. We did not see any effect on GR translocation indicating that loss of AMPK does not affect GR trafficking in macrophages (Fig.S1B,C) .
The main mode of action of GR is as a transcriptional regulator. Therefore, we sought to determine how loss of AMPK alters the gene regulatory activity of GR. Kourtzelis et al., 2019; Liao et al., 2011; Shouval et al., 2014) .
Among the 57 genes having a known function, 22 were involved in either phagocytosis, autophagy and/or macrophage polarization (Supplementary Table 2 ). Phagocytosis of apoptotic cells, also known as efferocytosis, is a core function of macrophages during tissue repair and inflammation, and has been shown to be a key factor in the resolution of acute lung inflammation (Fadok et al., 1998; Huynh et al., 2002; Nepal et al., 2019) , and for efficient tissue repair (Köröskényi et al., 2011) .
To determine whether AMPK alters the ability for GCs to induce efferocytosis, we performed in vitro and ex vivo efferocytosis assays. While Dex treatment increased efferocytosis of apoptotic thymocytes (simulating cells recruited during infections such as sepsis) in WT BMDMs (+62%), AMPKa1 deficient macrophages were unable to efficiently phagocytose the apoptotic cells in response to Dex stimulation (Fig.2B ). This was confirmed ex vivo, in a sterile inflammation model where CD64 pos macrophages were sorted from post-injured regenerating skeletal muscle and were tested for their capacity to engulf apoptotic myoblasts after a single Dex injection during the resolution of inflammation, i.e. at 2.5 days Varga et al., 2013) . Three subsets of macrophages were sorted as: pro-inflammatory Ly6C pos macrophages, Ly6C neg anti-inflammatory macrophages and a Ly6C int subset of macrophages that are shifting from pro-to anti-inflammatory profile Varga et al., 2013 Varga et al., , 2016b (Fig.S4B) . In WT mice, Dex treatment of mice 15 hours prior to macrophage isolation increased by +42% the phagocytic capacity of Ly6C int macrophages assessed by the increased GeoMean Fluorescent Intensity of macrophages having engulfed apoptotic myoblasts (Fig.2C, Fig.S4B ). On the contrary, in AMPKa1 deficient animals, Ly6C int macrophages from regenerating muscle did not modify their phagocytic capacity upon Dex treatment (Fig.2C, Fig.S4B ). Of note, Ly6C pos and Ly6C neg did not show changes in their phagocytic capacity upon the various conditions (Fig.S4B ). These data are in accordance with the impaired gene regulation in AMPK deficient macrophages upon Dex treatment and 8 indicate that loss of AMPK abrogates GC-induced efferocytosis, a major process contributing to the resolution of inflammation.
Next we tested whether the AMPK-dependent increased capacity of efferocytosis was associated with an acquisition of a pro-resolving inflammatory profile upon Dex treatment. WT and AMPKa1 -/-BMDMs were treated with LPS (Fig.2D ) or with DAMPs ( Fig.2E) 
AMPKa1 in macrophages is required for the glucocorticoid-induced effects on post-injury muscle regeneration
Both inflammatory polarization and efferocytosis are major contributors to macrophage dependent resolution of inflammation. Therefore, we determined how loss of AMPKa1 in macrophages influence GC suppression of inflammation in two mouse models, the skeletal muscle regeneration (representative of sterile inflammation) and the lethal endotoxin shock (mimicking systemic inflammation upon bacterial challenge). To assess how GR-AMPK crosstalk in macrophages regulates regeneration of muscle in vivo, we used a tissue specific knockout of AMPKa1 in the myeloid lineage (LysM-a1 -/-). Macrophages isolated from LysMa1 -/-mice respond to Dex in a similar way as cells from global knockout mice (AMPKa1 -/-) in vitro ( Fig.1G and Fig.S1D ) making them an ideal model for in vivo investigation of GR-AMPK cross-talk. Both WT and LysM-a1 -/-mice were injected in the Tibialis Anterior muscle with cardiotoxin (CTX) to induce muscle damage, a model in which the resolution of inflammation occurs around day 2 Varga et al., 2016a) . When Dex (0.05 mg/kg) was given from day 0 or 1 or 2 after injury (i.e. before and during the resolution of inflammation) until day 7, muscle regeneration was strongly impaired in WT muscles, as shown by the remaining inflammation and necrotic myofibers at day 8 as compared with PBS treated muscle injured animals ( Fig.S5A) , confirming that the initial pro-inflammatory phase, preceding the anti-inflammatory repair phase, must not be shortened for an efficient muscle regeneration (Perdiguero et al., 2011) . When Dex was administered from day 3 to day 7 after injury at 0.1 mg/kg, WT muscles exhibited a higher number of small myofibers than control muscles 14 days after injury ( Fig.S5B ). This suggests that daily exposure to Dex, even at low doses, induced myofiber atrophy, which is a well-known GC side effect (Schakman et al., 2009; Shimizu et al., 2011) . We then injected a single dose of Dex at day 3 after injury. Here again, injection of a single 1 mg/kg GC dose induced myofiber atrophy (Fig.S5C) . We therefore used a single 0.1 mg/kg GC dose at day 3 after injury, which did not cause any detrimental reduction in myofiber size in WT animals ( Fig.S5D ), and we analyzed GC effects on the maturation of myofibers, which is an indicator of the regeneration process (Fig.3A) . Sarcoplasm contains myosin heavy chains (MHC), which compose the contractile apparatus. During adult skeletal muscle regeneration, the first MHC expressed in new regenerating myofibers is the embryonic form of MHC (embMHC), that is further replaced by mature forms of MHC (fast or slow) (Whalen et al., 1990) , including MHCI (slow-twitch, oxidative), MHCIIa (fast-twitch, oxidative), MHCIIb (fast-twitch, glycolytic) and MHCIIx (fast-twitch, glycolytic), which are associated with myofiber metabolism and contractile properties (Schiaffino, 2018) . genotype . Finally, we did not find any alteration of embMHC expression in Dex treated LysM-a1 -/-muscles as compared with vehicle treated LysM-a1 -/-muscles ( Fig.3B ,C), suggesting that Dex had no effect on myofiber maturation when AMPKa1 was absent in macrophages. These data show that a single Dex injection accelerated the maturation of regenerating myofibers in a macrophage AMPKa1-dependent manner. At day 28 after injury, embMHC was not detected anymore, and was replaced by MHCIIa, MHCIIb and MHCIIX in TA muscle of each group, whereas almost no MHCI myofibers were observed (Fig.3D ). No effect of Dex treatment was observed on WT mice. However, a decrease of the expression of MHCIIa (-32%, representative of 5% of the total myofibers) and an increase of that of MHCIIb (+15%, representative of 11% of the total myofibers) was observed in LysMa1 -/-mice as compared with WT ( Fig.3D ). Dex treatment reversed that phenotype in LysM-a1 -/-mice (Fig.3D) . These results show that the absence of AMPKa1 in macrophages impacted the expression of MHC in regenerating myofibers, and suggested that it lifted an inhibitory mechanism by which Dex treatment alters MHC expression, which was not observed in the WT.
AMPKa1 in macrophages is required for glucocorticoid protection during acute lung inflammation and endotoxin shock
We next aimed to determine whether the effect of Dex on the resolution of inflammation depends on AMPK in a model of sepsis. WT and LysM-a1 -/-mice were treated with vehicle, 10 mg/kg LPS or LPS + 1 mg/kg Dex, before an intravenous injection of oleic acid to induce lung inflammation (Vettorazzi et al., 2015) . After 24 hours, mice were sacrificed and cells infiltrating into the lungs were counted in the broncho-alveolar lavage (BAL) fluid. LPS increased the number of cells in the BAL of both WT and LysM-a1 -/-mice (4 and 5-fold, respectively) (Fig.4A) . Strikingly, the repressive effects of Dex on the reduction of cell numbers in BAL were only observed in the WT, but not in mice lacking AMPK in myeloid cells.
Furthermore, we detected fewer pro-inflammatory macrophages in the WT mice after Dex treatment (-70%), but LysM-a1 -/-mice were unaffected (Fig.4B,C) . Strikingly according to the effects observed ex vivo, the effects of GCs were maintained on cytokine production, as we saw no effect on BAL cytokine content upon AMPKa1 deletion (Fig.4D, Fig.S6A ). INFg, TNFa, IL-6 and IL-10 (among others) were all increased in mice treated with LPS, and reduced by Dex treatment in both WT and LysM-a1 -/-mice (Fig.4D, Fig.S6A ). Nevertheless, at the tissue level, LPS treatment induced alveolar collapse in both WT and LysM-a1 -/-mice, which was partially recovered in WT mice treated with Dex, but not in LysM-a1 -/-mice (Fig.4E ). Both tissue damage and cytokine production are related to death during sepsis (Stearns-Kurosawa et al., 2011) . Therefore, we determined whether loss of AMPK in macrophages altered GC effects on survival. We did not see a difference in survival after 50 hours in WT or LysM-a1 -/-mice treated with LPS alone (Fig.4F) . However, when mice were treated with both LPS and Dex, we found that LysM-a1 -/-mice were more likely to die than WT mice (Fig.4G) . However,
Discussion
Here we demonstrate that GCs require AMPKa1 to efficiently polarize macrophages to an anti-inflammatory phenotype. GCs were able to activate AMPK in macrophages, and genetic deletion of AMPKa1 inhibited GR mediated anti-inflammatory macrophage polarization and functions. Intriguingly, regulation of well-known GR target genes concerning transrepression and transactivation were not affected, whereas a novel subset of genes involved in polarization and efferocytosis required AMPK activation. This had important implications: i) in vitro where GC-induced phagocytosis was abrogated in the absence of AMPK leading to defective acquisition of the anti-inflammatory status phenotype and functions, and ii) in vivo where GC treatment manifested in a delayed onset of muscle regeneration and inefficient inhibition of lung inflammation in LysM-a1 -/-mice, suggesting a key role of AMPK in mediating the anti-inflammatory effects of GCs in macrophages.
Only scant studies have reported a link between AMPK signaling and GR signaling, and all in metabolic organs and cells (Liu et al., 2016; Nader et al., 2010; Ratman et al., 2016) . Indirect AMPK activation is observed in muscle cells where dexamethasone treatment induces mitochondrial dysfunction leading to decreased ATP, thus activating AMPK (Liu et al., 2016) .
AMPK indirectly phosphorylates GR S211 via p38 in preadipocytes and hepatocytes, promoting GR transcriptional activity (Nader et al., 2010) . However, our results show that in macrophages, GR phosphorylation depended on AMPK completely separate from the p38
pathway. In addition, dexamethasone was shown to increase AMPK activity in hepatocytes while decreasing it in adipocytes (Christ-Crain et al., 2008) . Finally, a physical link between phospho-AMPK and phospho-GR was shown in complex with PPARa to increase the transcriptional activity of the latter upon starvation (Ratman et al., 2016) . These studies show that AMPK-GR interaction impacts on GR transcriptional activity. In our conditions, we found that GCs activate AMPK as efficiently as the potent and allosteric AMPK activator 991 in macrophages, indicating a previously unknown role of GCs in stimulating AMPK signaling.
Deletion of AMPK results in a profound change of Dex-mediated gene expression.
Interestingly, canonical and well-studied GR related genes (up or down regulated) were not affected by the loss of AMPK in macrophages. The induction of GC response element (GRE)
containing genes such as Gilz (Tsc22d3), Mkp1 (Dusp1) and Fkbp5 or the repression of genes with elements required for tethering such as Tnfa, Il6 and Ifng, were not affected by the loss of AMPK in macrophages and in the BAL during lung inflammation. Importantly, we did find a difference in the capacity for GC signaling in absence of AMPK to polarize macrophages towards an anti-inflammatory phenotype. For example, we found key genes, such as Klf4, Nr1h3 and Il10rb all down-regulated in the AMPK knockout macrophages after treatment with LPS or DAMPs and Dex. We also saw an effect of GCs on the expression of Lamtor subunits 1-5, down regulating them in an AMPK dependent manner. The LAMTOR complex is a known regulator of mTOR, with genetic ablation of LAMTOR decreasing mTOR activity in immune cells (Hosokawa et al., 2017) . This effect was only observed in WT cells, indicating a crosstalk between GCs and AMPK in regulating mTOR. Similarly, GC mediated upregulation of the GR co-activators Ncoa2, Ncoa5 and Ncoa6 was dependent on intact AMPK signaling. NCOA proteins are known to control the target and directionality of gene regulation by GR (Petta et al., 2016) , thus as AMPK regulates the expression of these, adding a further layer of AMPKmediated regulation of GC signaling. Interestingly we found also a substantial fraction of genes that were Dex down-regulated in the absence of AMPK, but not in WT cells. This Dex regulation unleashed in AMPK knockout macrophages was affecting genes annotated for regulation of proliferation and mitosis. This could be interesting for macrophage homeostasis since recovery/anti-inflammatory macrophages were shown to proliferate at the time of the resolution of inflammation during tissue repair (Arnold et al., 2007; Davies et al., 2013 ). Since we focused in this study on pro-versus anti-inflammatory functions of macrophages we did not follow this up in this study. GR phosphorylation at S211 may also be involved in the AMPK control of non-canonical GR signaling. Previous reports have shown that phospho-deficient (S211A) and phospho-mimetic (S221D) have opposite effects on GR transcriptional activity, and on binding to the MED14 subunit of the Mediator complex (Chen et al., 2008) . While the authors only confirmed one interaction, the implication remains that differential phosphorylation status of GR, regulated by different kinases, can alter interaction with other co-factors, and thus the target genes of GR (Galliher-Beckley and Cidlowski, 2009). Indeed, this also applies to the phosphorylation status of GR co-factors, for example GRIP-1 phosphorylation can alter the transcriptional activity of GR (Rollins et al., 2017) . However, the question how AMPK can interact with various GR cofactors is still open.
While the above-mentioned genes illustrate an AMPK-dependent regulation of non-canonical GR transcriptional activity, our analysis of the enrichment of genes exhibiting specific transcription factor binding sites indicated that FOXO3 binding site was enriched in genes upregulated in WT macrophages upon Dex treatment and in genes downregulated in AMPK KO macrophages. FOXO3 is a direct target of AMPK (Greer et al., 2007) . Lutzner et al. (Lützner et al., 2012) proposed that upon metabolic stress (high cortisol and high AMP), FOXO3 is an indirect GR target through the activation of SGK1 that alleviates the inhibition of Foxo3 transcriptional activity, which is synergized with the activation of FOXO3 transcriptional activity by AMPK. FOXO3 was shown to be required for the differentiation of monocytes into macrophages via activation of AMPKa1 and autophagy (Zhang et al., 2017b) and to promote anti-viral response in macrophages (Zhang et al., 2019b) . Strikingly, FOXO3 is involved in the GC-driven anti-inflammatory response in Systemic Lupus Erythematosus through the reinforcement of the blockage of NF-KB activity (Lu et al., 2016) .
GC/GR signaling enhances the efferocytic properties of macrophages (Giles et al., 2001; Heasman et al., 2003; Stolberg et al., 2015) , for instance, by increasing the expression of
Mertk or Anxa1 as a core aspect of their anti-inflammatory effects (Koenen et al., 2018; Yona and Gordon, 2007; Zizzo et al., 2012) . Efferocytosis is associated with macrophage polarization state since it induces the acquisition of an anti-inflammatory/resolving phenotype (Fadok et al., 1998; Han et al., 2016; Huynh et al., 2002; Zhang et al., 2019a) , thus provides a bridge in macrophage function across sterile and LPS induced inflammation. In that context, our results show that genes downregulated in AMPK-deficient macrophages upon GC treatment were associated with autophagy and/or phagocytic processes. We previously showed that AMPK is required for the shift of macrophage phenotype upon phagocytosis of apoptotic cells ). Here we show that functionally, AMPK-deficient macrophages did not increase their phagocytic activity upon GC treatment. Consequently, LPS-or DAMPs-treated AMPK-deficient macrophages did not respond to GCs and were not able to shift towards an anti-inflammatory profile nor to acquire the promyogenic function of anti-inflammatory macrophages.
In vivo, the consequence of an impaired acquisition of an inflammatory/resolving phenotype of macrophages upon GC treatment results in a delay and alteration of the return to homeostasis in a model of tissue repair, assessed by the alteration of myosin heavy chain expression in regenerating skeletal muscle. It also strongly impacts the response of the tissue to a severe acute inflammation (in a lung injury model) where AMPK is required for macrophages to respond to Dex treatment in order to dampen the inflammation and recover the tissue integrity, and survival. These results implicate a convergence, and interdependence of GR and AMPK in the anti-inflammatory response that is independent on reduction of cytokine expression and is therefore a so far overlooked important aspect of mechanism of GC usage in the clinics.
Altogether, our data demonstrate a dependence of GR on AMPK in the regulation of inflammation, through a non-classical pathway in macrophages. This has clear implications for the role of GR signaling on macrophage function depending on the energy status of the cell, and could help identification of new small molecule strategies to enhance GC action in a clinical setting.
Experimental procedures
Animal models 1mg/kg or cyclodextrin (1 mg/kg) vehicle control. After 30 minutes, mice were injected intravenous (i.v.) with 2.6 µl/g oleic acid (Sigma-Aldrich, O1008) as a solution of 40% oleic acid in 1% bovine serum albumin (Sigma-Aldrich, A3912) as previously described (Vettorazzi et al., 2015) . Mice were killed 24 h later and bronchoalveolar lavage (BAL) was performed by instilling the lungs with 1mL of BAL fluid (PBS, 10 mM EDTA, 1% BSA) 3 times.
Analysis of lung immune cells, total cell counts and FACS
Cells isolated by BAL were centrifuged, washed with BAL fluid and red blood cells lysed.
Resulting cells were counted using a hemocytometer and normalized to the total amount of BAL fluid recovered. For FACS, cells were suspended in BAL fluid containing FcɣRII/III block (eBiosciences, 1:300), washed then incubated with antibodies against CD45 (APC, Invitrogen 30-F11, 1:300), CD11b (FITC, Invitrogen M1/70, 1:300), F4/80 (AF700, Invitrogen BM8, 1:300), Ly6G (Pe-Cy7, Invitrogen RB6-8C5, 1:300), Ly6C (PerCP-Cy5.5, eBiosciences HK1.4, 1:300). After washing, cells were analyzed immediately using a flow cytometer (LSRII, BD). Data were analyzed using FlowJo software.
Cytokine multiplex
Cytokines were determined in BAL fluid using a Cytokine & Chemokine Convenience 36-Plex
Mouse ProcartaPlex Panel 1A (ThermoFisher) using a Bio-plex 200 System (BioRad).
Samples below the detection threshold were excluded from analysis.
Histological analysis and in vivo immunostaining
TA muscles were mounted on piece of cork and fixed with tragacanth gum (VWR, 24437.260) before being frozen in isopentane cooled by liquid nitrogen. Muscles were stored at -80°C. TA muscles were sectioned with cryomicrotome (NX50, Microm) in 10 μm thick sections and slides were kept at -80°C. Slides were first stain with Hematoxilin and Eosin to check cardiotoxin injection and immunofluorescence was performed only on muscles that showed at least 90% of their area occupied by regenerating myofibers (i.e. exhibiting central nuclei). For immunofluorescence experiments, slides were incubated with Triton x100 0.5%, saturated with bovine serum albumin (BSA) 2% and were incubated overnight with primary anti-body (see Table1) . Slides were washed with PBS and incubated with secondary antibodies (see Table1) . Sections were soaked for 10 s in Hoechst solution H 33342 (Sigma-Aldrich, B2261, After BAL, lungs were fixed in 4% PFA overnight, then transferred to 70% ethanol. Fixed lungs were processed and embedded into paraffin, then cut to 5 µm sections using a microtome (Leica RM2255). Slides were then stained with hematoxylin and eosin, and imaged using an
Olympus BX41 microscope at 20X magnification.
Bone marrow-derived macrophages
Macrophages were obtained from bone marrow precursors as previously described . Total bone marrow was isolated from mice by flushing the femur and tibiae bone marrow with culture medium. Extracted bone marrow was cultured in DMEM high glucose high pyruvate (Gibco, 11995065) containing 20% of FBS, 1% of penicillin/streptomycin, 1% of fungizone and 30% of L929 conditioned medium for 5 to 7 days. L929 secrete high levels of Macrophage Colony-Stimulating Factor (MCSF) that triggers macrophage differentiation.
L929 conditioned medium was obtained after 10 days of L929 cells culture with DMEM containing 10% FBS.
DAMPs -Damaged associated molecular patterns from muscle
DAMPs were obtained from ischemia-injured muscles. Briefly, mice hindlimb underwent an ischemia for 2 hours. After 20 hours of reperfusion, all hindlimb muscles were harvested.
Three mice were pooled for each substrate. Once harvested, muscles were digested with Mammalian cell lysis buffer (Sigma-Aldrich, MCL1). Two tungsten beads were added in samples to homogenize the muscle extract with a Tissue lyser. After centrifugation, samples were sonicated and supernatant was recovered, pooled, and stored at -80°C.
Macrophage inflammatory status
Macrophages were seeded at 54,000 cells/cm 2 in DMEM containing 10% of FBS on glass coverslips in 12-well plates. Cells were treated with muscle DAMPs (1 μg/ml) or LPS (100 ng/ml for 24 hours and Dex (Sigma-Aldrich, D4902, 1x10 -8 M) was further directly added in the well for 6 hours. Cells were fixed with PFA 4%, permeabilized with Triton x100 0.5% and incubated for 1 hour with BSA 4%. Staining for CCL3 (Santa Cruz, sc-1383, 1:50), iNOS (Abcam, ab3523, 1:50), CD206 (Santa Cruz, sc-58987, 1:50), CD163 (Santa Cruz, sc-33560, 1:50 or BIOSS, bs-2527R, 1:100), TGFβ1 (Abcam, ab64715, 1:50) was performed as in . All samples of the same experiment were recorded in similar conditions (microscope, magnification, exposure time and binning). At least 10 pictures per condition were acquired at x20 magnification on an Axio Imager.Z1 microscope (Zeiss) connected to a CoolSNAP MYO CCD camera (photometrics) using MetaMorph Software. Quantification of macrophage markers was done manually using ImageJ software.
Quantitative Real-Time PCR and RNA-sequencing
Macrophages were seeded and allowed to adhere for 16 hours. Cells were then washed twice with PBS and medium was changed to Macrophage-SFM (Thermofisher, 12065074) with 1%
penicillin/streptomycin, 1% L-glutamine, 1% sodium pyruvate, 1% fungizone for 16 hours.
Cells were then treated with either vehicle (DMSO), 100 ng/mL LPS (Sigma, L6529), or DAMPS (1 μg/ml), 100 nM Dex (Sigma, D4902), or a combination of both for either 24, or 6 hours. Cells were then washed twice with PBS and total RNA extracted using Trizol (Invitrogen, 15596018), according to the manufacturer's protocol. For qRT-PCR, RNA was measured using a Nanodrop 1 µg of RNA was then reverse transcribed into cDNA (Applied Biosystems, High Capacity cDNA kit, 4368813) with additional RNase inhibitor (Invitrogen RNase OUT, 10777019). cDNA was quantified using a ViiA 7 (Applied Biosystems) and analyzed using the delta-delta CT method, relative to the average of WT vehicle treated samples. For RNA-seq, RNA integrity was assessed using a 2100 Bioanalyzer (Agilent) and samples with a RIN value of >6 were taken forward for library prep. Library prep and sequencing was performed using the Novaseq 6000 S4 platform at Novogene (Novogene, Beijing, China). Differential expression analysis was performed using DESeq2. Gene ontology and pathway analyses were performed using DAVID (Huang et al., 2009) , and ENRICHR (Kuleshov et al., 2016) . 
Primer List
Target
Myoblast -macrophage coculture
Macrophages were seeded at 54,000 cells/cm 2 in 12-well plates in DMEM 10% FBS. They were treated for 3 days with 1x10 -7 or 1x10 -8 M of Dex and washed. DMEM free serum was added for 24 hours to obtain conditioned medium. Myoblasts were obtained from TA muscles and were cultured in DMEM/F12 containing 20% FBS and 2% UltroserG (Pall Inc, 15950-017) as previously described . For proliferation studies, myoblasts were Imager.Z1 microscope (Zeiss) connected to a CoolSNAP MYO CCD camera (Photometrics) using MetaMorph Software. Quantification of proliferation (Ki67 pos cells) and of differentiation (number of myonuclei per cell) was done manually using ImageJ software.
Glucocorticoid receptor subcellular localization
BMDMs were seeded at a density of 20,000 cells in 96 well-plates. Medium was changed to
Macrophage-SFM (Thermofisher, 12065074) with 1% penicillin/streptomycin, 1% L-glutamine, 1% sodium pyruvate, 1% fungizone overnight. The following day, cells were treated with 100nM Dex (Sigma-Aldrich, D4902) for 1 hour, and fixed with 4% PFA for 15 minutes at 4°C.
PFA was removed, and samples were washed with PBS 3 times. Cells were permeabilized with permeabilization buffer (PBS, 0.1% TritonX-100) for 30 minutes at 4°C, then non-specific binding sites blocked with blocking buffer (PBS, 0.1% TritonX-100, 1% fetal calf serum) for 1 hour at room temperature, then overnight at 4°C. Cells were incubated with anti-GR antibody (Cell Signaling D8H2 3660, 1:200) overnight at 4°C. After washing with PBS 5 times, cells
were incubated with a fluorescently labelled secondary antibody (Thermofisher, A11037 antirabbit IgG Alexafluor 594) for 2 hours at room temperature. Cells were washed 5 more times and incubated with 1µg/mL DAPI (Sigma-Aldrich, D9542) for 10 minutes at room temperature.
Cells were washed twice more and retained in PBS for immediate imaging. Images were acquired using the ImageXpress MicroConfocal (Molecular Devices), at least 12 images were acquired per biological sample. Nuclear GR intensity was determined using ImageJ.
Western blot
AMPK/Raptor/ACC: Macrophages were seeded at 208,000 cells/cm 2 in 6-well plates. Cells were treated with Dex (Sigma-Aldrich, D4902, 1x10 -7 M or 1x10 -8 M) and 991 (Spirochem, 129739-36-2, 1 µM) for 0.5 to 1 hour in DMEM containing 10% of charcoal stripped serum (Gibco, 12676029). Total protein extract was obtained in cell lysis buffer containing 50 mM Tris-HCL (pH 7.5), 1 mM EDTA, 1 mM EGTA, 0.27 M sucrose, 1% triton, 20 mM glycerol-2-phosphate disodium, 50 mM NaF, 0.5 mM PMSF, 1 mM benzamidine, 1 mM Na 3 VO 4 and 1% cocktail phosphatase inhibitor 3 (Sigma-Aldrich, P0044). Thirty micrograms of protein were subjected to SDS-PAGE (100V) and transferred onto a nitrocellulose membrane overnight at 4°C, 30V. Blots were probed with antibodies against p-AMPKɑ (Cell Signaling, #2535, 1:1000), AMPKɑ (Cell Signaling, #2532, 1:1000), p-ACC (Cell Signaling, #3661, 1:1000), ACC (Cell Signaling, #3662, 1:1000), with β-actin (Sigma-Aldrich, A5316, 1:2000) as a loading control. p-AMPKa immunoblots and AMPKɑ immunoblots were performed on separated blot and each independent experiment was also performed on independent Western blot. Blots were quantified using ImageJ software and results represent (p-AMPKa/β-actin) ratio on (AMPKa/β-actin) ratio for each experiment and they are also normalized to the control condition.
GR/p38: Macrophages were seeded at confluency in 10cm plates, and changed to DMEM containing charcoal stripped serum (Sigma-Aldrich, F7524) overnight. The following day, cells were treated with vehicle (DMSO) or Dex (Sigma-Aldrich, D4902, 1x10 -7 M) for 1 hour. Cells were then washed twice in ice cold PBS and total protein was extracted using RadioImmunoprecipitation Assay (RIPA) buffer (50 mM Tris-HCl pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA) containing protease inhibitors (Roche, 04694124001), phosphatase inhibitor cocktail 2 (Sigma-Aldrich, P5726) and phosphatase inhibitor cocktail 3 (Sigma-Aldrich, P0044). 25 µg of protein was subjected to SDS-PAGE (100V) and transferred to a nitrocellulose membrane for 1 hour at 4°C, 100V. Blots were blocked with 5% BSA (Sigma-Aldrich) and probed with antibodies against p-GR (Cell Signaling, #4161, 1:1000), GR (Cell Signaling, #3660, 1:1000), p-p38 (Cell Signaling #4511, 1:1000), p38 (Cell Signaling, #8690, 1:1000) with β-actin (Sigma-Aldrich, A5316, 1:2000) or a-tubulin (Santa Cruz, sc-8035, 1:1000) as a loading control. Blots were quantified using ImageJ.
Ex vivo phagocytosis assay
TA muscle was damaged as described above. Two and a half days after injury, mice were treated with i.p. injection of Dex (Sigma-Aldrich, D2915, 1 mg/kg). At day 3, TA muscles were harvested, digested for 1 hour with collagenase (Roche, 11088831001, 1 mg/ml) in RPMI medium at 37°C. Digested muscles were filtered through 30 µm filter with DMEM containing 50% FBS. CD45 pos cells were isolated using magnetic sorting (Milteny Biotec, and 130-052-301) and were seeded at 190,000 cells per wells in 12-well plates in DMEM serum free. Primary myoblasts previously stained with PKH67 (Sigma-Aldrich, MINI67) were first submitted to 20 mM of H 2 O 2 for 20 minutes to induce necrosis before being added to wells at 1:3 ratio (570,000 myoblasts per condition). After 6 hours of phagocytosis, cells were for flow cytometry analysis.
In vitro phagocytosis assay
BMDMs were isolated as described above. After differentiation, 100,000 BMDMs per well were seeded into 12 well plates, allowed to adhere and medium changed to L929 conditioned medium with charcoal stripped serum. Simultaneously, thymuses were isolated from 2 mice, and treated over-night with Dex (Sigma-Aldrich, D4902, 1x10 -6 M) in RPMI-1640 (SigmaAldrich, R8758) to induce apoptosis. The next day, apoptotic thymocytes were washed with cold PBS and FCS to remove excess Dex, then 7x10 6 cells were incubated with CSFE (Thermofisher, C34554, 1:25000) for 20 minutes at 37°C. Labelled thymocytes were then added to BMDMs in a ratio of 5:1 and incubated at 37°C for 2.5 hours to allow phagocytosis.
A negative control was maintained at 4°C. Cells were then washed twice with PBS, and scraped into FACS buffer (PBS, 10mM EDTA, 1% BSA). The cell mixture was first blocked with anti-FcɣRII/III (eBiosciences, 14-0161-82) then stained with anti-F4/80 (Invitrogen, BM8, 1:300) and analysed on a flow cytometer (LSRII, BD). Data were analysed with FlowJo, with signal higher than the 4°C control considered a positive phagocytosis event.
Cytokine multiplex.
Mouse ProcartaPlex Panel 1A (ThermoFisher) using a Bioplex-200 System (BioRad).
Transcription factor binding site analysis
Genes up-or down-regulated by DEX were analyzed for over-represented transcription factor binding sites using the Single Site Analysis function from oPOSSUM-3 software (Kwon et al., 2012) . Sequences from 2000 bp upstream to 2000 bp downstream of the transcription start sites were analyzed against all the 29347 genes in the oPOSSUM database using a 0.4 conservation cutoff and a 85% matrix score threshold. Enriched transcription factor binding sites were ranked by Z-score and only the 15 highest scores were considered.
Statistical analysis
All experiments were performed at least using 3 independent primary cultures. For in vivo experiments, at least 4 mice were analyzed from three independent experiments for each group. Statistic tests were performed using GraphPad Prism software. Normality was tested 
